替尔泊肽与司美格鲁肽对2型糖尿病患者餐试中β细胞功能、胰岛素敏感性和血糖控制的影响
在德国2个临床研究中心开展的28周双盲随机安慰剂对照试验,纳入接受二甲双胍治疗的2型糖尿病患者,比较替尔泊肽15 mg、司美格鲁肽1 mg与安慰剂。基于混合餐耐量试验数据的模型分析显示,替尔泊肽较司美格鲁肽显著降低空腹血糖和总葡萄糖AUC,并改善胰岛素分泌率、胰岛素敏感性和胰高血糖素抑制。
要点
- 替尔泊肽较司美格鲁肽显著降低空腹血糖和混合餐耐量试验总葡萄糖AUC(P<.01)。
- 替尔泊肽较司美格鲁肽显著增加7.2 mmol/L血糖下的胰岛素分泌率(P<.05)。
- 替尔泊肽较司美格鲁肽显著降低总胰高血糖素AUC(P<.01)。
核心结论
- 结果提示替尔泊肽更优的血糖控制表现为空腹血糖和血糖波动控制的改善,源于胰岛素分泌率、胰岛素敏感性和胰高血糖素抑制的改善。
研究设计与样本
- 28周双盲、随机、安慰剂对照试验,在德国2个临床研究中心开展,纳入接受二甲双胍治疗的2型糖尿病患者,干预为替尔泊肽15 mg、司美格鲁肽1 mg和安慰剂。
主要发现
- 替尔泊肽较司美格鲁肽显著降低空腹血糖和混合餐耐量试验总葡萄糖AUC(P<.01)。
- 增量葡萄糖AUC在两种治疗间无显著差异,因此替尔泊肽更大的总葡萄糖AUC降低主要归因于对空腹血糖的更大幅度抑制。
- 替尔泊肽较司美格鲁肽实现更大的总胰岛素分泌率AUC降低(P<.01),同时胰岛素敏感性改善更大(P<.01)。
- 7.2 mmol/L血糖下的胰岛素分泌率在替尔泊肽组较司美格鲁肽组显著增加(P<.05),显示β细胞葡萄糖敏感性改善。
- 混合餐耐量试验衍生的β细胞葡萄糖敏感性增加但两种治疗间无显著差异;两种治疗均降低空腹胰高血糖素和总胰高血糖素AUC,替尔泊肽较司美格鲁肽显著降低胰高血糖素AUC(P<.01)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In a clinical study, tirzepatide, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1RA), provided superior glycemic control vs the GLP-1RA semaglutide. The physiologic mechanisms are incompletely understood. OBJECTIVE: This work aimed to evaluate treatment effects by model-based analyses of mixed-meal tolerance test (MMTT) data. METHODS: A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany. Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo. Main outcome measures included glycemic control, model-derived β-cell function indices including insulin secretion rate (ISR) at 7.2-mmol/L glucose (ISR7.2), β-cell glucose sensitivity (β-CGS), insulin sensitivity, and estimated hepatic insulin-to-glucagon ratio. RESULTS: Tirzepatide significantly reduced fasting glucose and MMTT total glucose area under the curve (AUC) vs semaglutide (P < .01). Incremental glucose AUC did not differ significantly between treatments; therefore, greater total glucose AUC reduction with tirzepatide was mainly attributable to greater suppression of fasting glucose. A greater reduction in total ISR AUC was achieved with tirzepatide vs semaglutide (P < .01), in the context of greater improvement in insulin sensitivity with tirzepatide (P < .01). ISR7.2 was significantly increased with tirzepatide vs semaglutide (P < .05), showing improved β-CGS. MMTT-derived β-CGS was increased but not significantly different between treatments. Both treatments reduced fasting glucagon and total glucagon AUC, with glucagon AUC significantly reduced with tirzepatide vs semaglutide (P < .01). The estimated hepatic insulin-to-glucagon ratio did not change substantially with either treatment. CONCLUSION: These results suggest that the greater glycemic control observed for tirzepatide manifests as improved fasting glucose and glucose excursion control, due to improvements in ISR, insulin sensitivity, and glucagon suppression.
引用
- Mather KJ, Mari A, Heise T, et al. Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test. J Clin Endocrinol Metab. 2024. PMID: 38795393. doi:10.1210/clinem/dgae319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。